Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sinovac Awarded High-Tech Status, Which Brings Lower Taxes And Other Government Benefits

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Sinovac Biotech has been granted high-tech enterprise status by three government departments and will get a lower tax rate, at 15 percent, from the standard rate of 25 percent, from 2008 to 2010, the company announced March 9

You may also be interested in...



China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D

SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D

China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D

SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D

Sinovac To Start Clinical Trials For Hep A Vaccine In Ukraine; First Overseas Steps

SHANGHAI - Sinovac has inked a deal with Ukraine-based Biolik Biopharmaceutical to conduct clinical trials for its inactivated hepatitis A vaccine Healive in Ukraine, the company announced on Sept. 15

Related Content

UsernamePublicRestriction

Register

SC071056

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel